4//SEC Filing
Belder Rene 4
Accession 0001273013-08-000070
CIK 0001273013other
Filed
Dec 23, 7:00 PM ET
Accepted
Dec 24, 10:51 AM ET
Size
18.4 KB
Accession
0001273013-08-000070
Insider Transaction Report
Form 4
PHARMACOPEIA INCPCOP
Belder Rene
VP, Clinical & Regulatory
Transactions
- Disposition to Issuer
Non-Qualified Stock Option (right to buy)
2008-12-23$0.20/sh−100,000$20,000→ 0 totalExercise: $3.95From: 2007-11-13Exp: 2016-11-13→ Common Stock (100,000 underlying) - Disposition to Issuer
Non-Qualified Stock Option (right to buy)
2008-12-23$0.20/sh−4,167$833→ 0 totalExercise: $4.67From: 2008-02-28Exp: 2017-02-28→ Common Stock (4,167 underlying) - Disposition to Issuer
Common Stock
2008-12-23−31,769.7→ 0 total - Disposition to Issuer
Non-Qualified Stock Option (right to buy)
2008-12-23$0.20/sh−21,000$4,200→ 0 totalExercise: $3.63From: 2009-04-01Exp: 2018-04-01→ Common Stock (21,000 underlying) - Tax Payment
Common Stock
2008-12-23−11,780→ 31,769.7 total - Disposition to Issuer
Non-Qualified Stock Option (right to buy)
2008-12-23$0.20/sh−15,209$3,042→ 0 totalExercise: $3.84From: 2009-02-25Exp: 2018-02-25→ Common Stock (15,209 underlying) - Disposition to Issuer
Incentive Stock Option (right to buy)
2008-12-23$0.20/sh−74,791$14,958→ 0 totalExercise: $3.84From: 2009-02-25Exp: 2018-02-25→ Common Stock (74,791 underlying)
Footnotes (3)
- [F1]Disposed of in connection with tax withholding obligation of the reporting person upon the vesting of 40,000 restricted stock units as a result of the consummation of the transactions contemplated by a merger agreement (the "merger agreement") by and among Pharmacopeia, Inc. ("Pharmacopeia"), Ligand Pharmaceuticals Incorporated ("Ligand"), Margaux Acquisition Corp., a wholly-owned subsidiary of Ligand, and Latour Acquisition, LLC, a wholly-owned subsidiary of Ligand.
- [F2]Disposed of pursuant to the merger agreement in exchange for approximately 19,014.17 shares of Ligand common stock having a market value of $2.58 per share on the effective date of the merger and $9,848.61 in cash, without interest. In addition, the reporting person received one contingent value right ("CVR") for each share of the Pharmacopeia common stock disposed of in the merger by the reporting person. The CVRs provide each holder the right to receive approximately $0.50 per share if Ligand enters into a license, sale, development, marketing or option agreement with respect to any product candidate from Pharmacopeia's dual angiotensin and endothelin receptor antagonist program (other than any agreement with Bristol-Myers Squibb Company or any of its affiliates) on or prior to December 31, 2011.
- [F3]This option was canceled in connection with Pharmacopeia's offer to purchase all outstanding options, whether vested or unvested, to purchase shares of Pharmacopeia common stock, par value $0.01 per share, which was consummated on December 23, 2008. The reporting person received a cash payment of $0.20 per share of common stock issuable upon exercise of each such option.
Documents
Issuer
PHARMACOPEIA INC
CIK 0001273013
Entity typeother
Related Parties
1- filerCIK 0001382436
Filing Metadata
- Form type
- 4
- Filed
- Dec 23, 7:00 PM ET
- Accepted
- Dec 24, 10:51 AM ET
- Size
- 18.4 KB